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Parkinson’s disease (PD) is a neurological disorder that is associated with both motor 
and non-motor symptoms (NMS). The management of PD is primarily via pharmaceu-
tical treatment; however, non-pharmaceutical interventions have become increasingly 
recognized in the management of motor and NMS. In this review, the efficacy of physical 
activity, including physiotherapy and occupational therapy, as an intervention in NMS 
will be assessed. The papers were extracted between the 20th and 22nd of June 2016 
from PubMed, Web of Science, Medline, Ovid, SportsDiscuss, and Scopus using the 
MeSH search terms “Parkinson’s,” “Parkinson,” and “Parkinsonism” in conjunction 
with “exercise,” “physical activity,” “physiotherapy,” “occupational therapy,” “physical 
therapy,” “rehabilitation,” “dance,” and “martial arts.” Twenty studies matched inclusion 
criteria of having 10 or more participants with diagnosed idiopathic PD participating in 
the intervention as well as having to evaluate the effects of physical activity on NMS in 
PD as controlled, randomized intervention studies. The outcomes of interest were NMS, 
including depression, cognition, fatigue, apathy, anxiety, and sleep. Risk of bias in the 
studies was evaluated using the Cochrane Collaboration’s tool for assessing risk of bias. 
Comparability of the various intervention methods, however, was challenging due to 
demographic variability and methodological differences. Nevertheless, physical activity 
can positively impact the global NMS burden including depression, apathy, fatigue, 
day time sleepiness, sleep, and cognition, thus supporting its therapeutic potential in 
neurodegenerative conditions such as PD. It is recommended that further adequately 
powered studies are conducted to assess the therapeutic role of physical activity on 
both motor and non-motor aspects of PD. These studies should be optimally designed 
to assess non-motor elements of disease using instruments validated in PD.
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inTRODUCTiOn
Parkinson’s disease (PD) is a progressive bradykinetic disorder commonly presenting uni-
laterally, affecting over 1% of people over 55 years of age and marked by the degeneration of 
dopaminergic neurons in the substantia nigra (1, 2). While PD is most commonly associated 
with motor symptoms, such as tremor, rigidity, and gait disorders, there are numerous non-
motor symptoms (NMS) associated with the condition such as hyposmia, constipation, cognitive 
impairment, anxiety, and depression (3). The treatment of the diverse array of NMS associated 
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with PD can be challenging and non-pharmacological options 
such as education, support services, and exercise are likely to 
be underutilized due to various reasons that include limited 
knowledge on its therapeutic potential. In recent times, there 
is a growing body of evidence which supports the beneficial 
effects of non-pharmacological therapy, in particular, the effect 
of exercise on both motor and NMS (4).
Physical activity has been found to influence the brain’s 
neurochemistry and plasticity, through the upregulation of 
neurotrophins such as brain-derived nerve factor (BDRF) and 
nerve growth factor (NGF) in rat models (5, 6). BDRF has been 
suggested to increase turnover rate of dopamine in  vitro and 
provide a neuroprotective role in nigral dopamine neurons (7). 
Additionally, BDRF has been thought to regulate branching and 
remodeling of axons and dendrites, whose length is reduced in 
PD (8, 9). NGF has also been linked to neuroprotection through 
stabilizing intracellular calcium which may influence L-type 
calcium channels know to mediate synaptic transmission of 
dopamine in rat midbrains (10, 11). The increased presence of 
such chemicals in the brain could help impede the progression 
of PD and potentially provide a neuroprotective effect.
Additionally, the relationship between exercise and endor-
phins has long been studied, as the opioid peptide can produce 
feelings of euphoria and well-being. The hormone is produced 
by the pituitary gland and hypothalamus during exercise, as 
well as excitement and pain (12). Endorphins are hypothesized 
to improve mood, such as depression and anxiety, via two dif-
ferent mechanisms; through binding to opioid receptors in the 
frontal cortex and limbic region, areas involved with mood; and 
by interacting with other neurotransmitters, such as dopamine, 
which also partake in improvement of mood (13).
Physical activity is becoming more popular for the treatment 
of chronic disease such as PD. However, the focus of many 
studies, to date, has primarily been on motor symptoms, with 
fewer studies assessing its effect on NMS. This review is aimed at 
determining the best available current evidence on the effects of 
various forms of exercise on NMS in PD.
MeTHODS
Literature Search
This review included articles which met  all of the following 
criteria: 10 or more participants diagnosed with idiopathic 
PD completing the intervention, participants needed to be 
randomized, and studies must evaluate the effect of physical 
activity on NMS in PD. For the purpose of this review, physical 
activity is defined as “any bodily movement produced by skeletal 
muscles that result in energy expenditure” (14). Papers were 
excluded if published prior to 1996 and did not assess global 
or specific NMS as a variable of interest. Additionally, papers 
needed to score a minimum score of 2 out of a maximum 5 
according to the JADAD Scale, a short and widely used method 
to assess the quality of a report (15). The literature search was 
conducted using six databases between the 20th and 22nd of 
June 2016 (PubMed, Medline, Ovid, SportsDiscuss, Scopus, 
and Web of Science). Search terms included the MeSH terms 
for “Parkinson’s,” “Parkinson,” and “Parkinsonism” combined 
with “exercise,” “physical activity,” “dance,” “physiotherapy,” 
“occupational therapy,” “physical therapy,” “rehabilitation,” and 
“martial arts.” Titles and abstracts were read with papers not 
meeting selection criteria being discarded, and those remaining 
were read in full to check for suitability, in accordance with the 
Preferred Reporting Items for Systematic and Meta-Analyses 
(PRISMA) (see Figure S1A in Supplementary Material) (16). 
The protocol for this systematic review was registered with 
PROSPERO on the 8th of April 2016.
Data extraction
Data extraction was completed by one reviewer confirmed by 
a fellow author. Relevant articles meeting the inclusion criteria 
were reviewed with all relevant information, such as type of 
intervention, frequency, duration, and mode of delivery, along 
with outcomes.
Outcomes of interest
The outcomes of interest were both global and specific NMS. 
Those assessed globally included instruments such as the Unified 
Parkinson’s Disease Rating Scale Part 1 (UPDRS-1) and the Non-
Motor Symptom Scale (NMSS), as well as more focused assess-
ments of cognition, depression, fatigue, apathy, anxiety, and sleep 
using validated instruments.
ReSULTS
The database search yielded 20 papers which met inclusion 
criteria (see Table 1).
Participants
The number of participants in the studies ranged from 18 (17) to 
191 (18). The majority of studies had a higher male to female ratio 
(18–31), apart from two which had equal proportions (32, 33) and 
three which had a higher proportion of females (17, 34, 35). One 
study did not mention the ratio of male to female participants 
(36). The overall age range was from 40 to 89 years (17–36).
intervention and Activity Type
The majority of studies conducted 2–4  sessions/week, each 
lasting between 20 and 90 min (17, 19–23, 25–31, 33–36), with 
some studies opting for increased or decreased frequency and 
length (18, 24, 32). The total intervention period varied greatly, 
with the shortest duration being 4 weeks (34), and the longest 
being 3 years (32). The most common duration was 12 weeks, 
with five studies opting for that duration (20, 22, 25, 30, 31). 
Eleven studies had a short intervention period between 4 and 
12 weeks (17, 18, 20, 22, 25, 26, 30, 31, 33–35), six had medium 
intervention durations between 3 and 6 months (19, 23, 24, 27, 
28, 36), and three had long intervention periods of 1 year (21), 
2 years (29), and 3 years (32). The studies all utilized an active 
intervention, the physical activity including aerobic training 
(30, 35), treadmill training (19, 28, 33), and walking (24); resist-
ance training (28, 29); balance training, Tai Chi (20, 27), and 
Baduanjin Qigong (24, 35); as well as customized programs such 
as physiotherapy (32), OT (18, 26), physiotherapist-supervised 
exercise, self-supervised exercise (34), group exercise (34), active 
TABLe 1 | Study characteristics.
Reference Participants Dropouts  
(N)
Frequency Length of  
session
Duration of 
intervention
Activity type Design JADAD 
score
Burini et al. 
(35)
29 AeT = 2 3/week 45 min 7 weeks  – Aerobic training (AeT)
 – Qigong (GQ)
Randomized (PD) 
cross over trial
5
GQ = 2
Clarke et al. 
(26)
39 OT = 1 3/month 45 min 2 months  – Occupational  
therapy (OT)
Randomized control 
(PD) – no exercise
5
Control = 1
David et al. 
(29) 
51 PRET = 5 2/week Not specified 24 months  – Progressive resistance 
exercise training (PRET)
 – Modified fitness 
counts (mFC)
Randomized (PD) 
into 2 intervention 
groups
5
mFC = 7
Duncan and 
Earhart (21)
62 AT = 16 2/week 1 h 12 months  – Argentine tango (AT) Randomized control 
(PD) – no exercise
5
Control = 11
King et al.  
(34)
78 Home = 0 3/week 1 h 4 weeks  – Home exercise program
 – Individual exercise  
program
 – Group exercise program
Randomized (PD) 
into 3 intervention 
groups stratified by 
comorbidity level
5
Individual = 0
Group = 1
Modugno 
et al. (32)
24 Physio = 2  – Physio: 3/week
 – AT: 2–4/month
 – Physio: 2–3 h
 – AT: 6 h
3 years  – Physiotherapy
 – Active theater training
Randomized controls 
(PD) – physiotherapy, 
stratified by age, 
sex, years of PD 
diagnosis and 
pharmacological 
treatment
5
Active T = 2
Nadeau et al. 
(19)
45 STT = 16 3/week 1 h 24 weeks  – Speed treadmill  
training (STT)
 – Mixed treadmill  
training (MTT)
Randomized control 
(PD) – no exercise
5
MTT = 19
Control = 22
Pohl et al.  
(17)
18 RGR = 0 2/week 1 h 6 weeks  – Ronnie Gardiner Rhythm  
and Music Method  
(RGR)
Randomized control 
(PD) – no exercise
5
Control = 2
Shulman  
et al. (28)
80 HIT = 3 3/week Varied 3 months  – High-intensity treadmill 
training (HIT)
 – Low-intensity treadmill 
training (LIT)
 – Stretching and resistance 
training (S–R)
Randomized (PD) 
into 3 intervention 
groups
5
LIT = 4
S–R = 5
Sturkenboom 
et al. (18)
191 OT = 3 Varied Mostly 1 h 10 weeks  – Occupational therapy  
(OT)
Randomized control 
(PD) – no exercise 
using minimization 
algorithm
5
Control = 6
Winward  
et al. (31)
39 Gym = 0 Varied 30–45 min 12 weeks  – Gym-based exercise 
program
Randomized with 
non-gym control
5
Control = 0
Bridgewater 
and Sharpe 
(30)
26 Aerobic = 0 2/week 1 h 12 weeks  – Aerobic exercise Randomized with 
inactive control
4
Control = 0
Nocera  
et al. (27)
23 TC = 2 3/week 1 h 16 weeks  – Tai Chi (TC) Randomized control 
(PD) – non-contact
4
Control = 0
Teixeira-
Machado 
et al. (36)
30 FPTP = 0 2/week 1 h 25 weeks  – Feldenkrais physical  
therapy program (FPTP)
Randomized control 
(PD) – educational 
lectures
4
Control = 0
Xiao and 
Zhuang (24)
96 BQ = 3  – BQG: 4/week
 – Walking: daily
 – BQG: 15 min
 – Walking: 30 min
6 months  – Baduanjin Qigong with 
walking (BQ)
 – Walking
Randomized control 
(PD) – walking
4
Walking = 4
Cholewa  
et al. (20)
70 Physio = 0 2/week 1 h 12 weeks  – Physiotherapy Randomized control 
(PD) – no exercise
2
Control = 0
Cugusi  
et al. (25)
20 NW = 0 2/week 1 h 12 weeks  – Nordic walking (NW) Randomized control 
(PD) – no exercise
2
Control = 0
(Continued)
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Reference Participants Dropouts  
(N)
Frequency Length of  
session
Duration of 
intervention
Activity type Design JADAD 
score
Miyai  
et al. (33)
24 Treadmill = 1 3/week 45 min 1 month  – Body weight-supported 
treadmill training
Randomized with 
conventional physical 
therapy control
2
Physio = 3
Park et al. (23) 31 ESG = 1 3/week 1 h 48 weeks  – Early start exercise (ESG)
 – Delayed start exercise (DSG)
Randomized (PD) 
into 2 intervention 
groups
2
DSG = 0
Rios 
Romenets 
et al. (22)
33 Tango = 0 2/week 1 h 12 weeks  – Argentine tango (AT) Randomized control 
(PD) – self-directed 
exercise
2
Control = 1
TABLe 1 | Continued
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theater training (32), Argentine tango (21, 22), early and delayed 
start exercise modified for PD (23), Feldenkrais physical therapy 
program (36), Nordic Walking (25), modified fitness counts (29), 
gym-based exercise program (31), and the Ronnie Gardiner 
Rhythm and Music Method (17) (see Table 2).
Medication
Nine of the studies analyzed the participants on medication (17, 
22, 25, 27, 28, 31, 33–35); however, three of those had a change 
in medication as exclusion criteria (17, 22, 33). Three studies (21, 
24, 29) assessed the participants off their medication, one (23) did 
not include anyone on levodopa, and seven studies did not specify 
participant medication status (18–20, 26, 30, 32, 36).
Failed to Complete Study
Five of the studies did not have failures to complete (20, 25, 30, 
31, 36), while 15 did have participants not completing the study 
(17–19, 21–24, 26–29, 32–35). Reasons for failure to complete 
were not wanting to continue (18, 21), scheduling issues (18, 19, 
21, 27), commute difficulties (28), changes in medication (17, 19, 
33), other comorbidities (17–19, 21, 28), received other interven-
tion simultaneously (18), musculoskeletal injuries (19, 35), motor 
vehicle accident (19), unreturned questionnaires (26), could not 
continue due to health reasons (22), poor compliance (23, 35), 
inability to commit to sessions (34), hospitalization (24), too 
much to handle, physical decline, physically unable, underwent 
deep brain stimulation, moved away (21), family demands (21, 
28, 34), and no clear explanation (18, 22, 24). One study did not 
outline reasons for dropouts (29).
Measurement Tools
Global NMS were measured with UPDRS part 1 or the revised 
MDS-UPDRS part 1 (19–21, 32, 33), and the NMSS (25). 
Depression was measured using the Beck Depression Inventory 
(BDI/BDI-II) (18, 19, 22, 23, 25, 28, 35, 36), the Hamilton 
Depression Rating Scale (Ham-D) (32), the Levine–Pilowsky 
Depression Questionnaire (LPDQ) (30), and the Hospital 
Anxiety and Depression Scale (HADS) (26). Cognition was 
evaluated using the Mini Mental State Exam (MMSE) (19, 36), 
the Montreal Cognitive Assessment (MoCA) (22), subsections 
of the Cognitive Assessment Battery (CAB) (17), Stroop Test (17, 
27, 29), and the Brief Test of Attention (BTA) (29). Some stud-
ies chose to use subsections of the cognitive tests as previously 
mentioned (27,  29). Daytime sleepiness was measured with 
Epworth Sleepiness Scale (ESS) (32), and sleep quality with 
Parkinson Sleep Scale (PSS) (24). Fatigue was analyzed by the 
16-item Parkinson’s Disease Fatigue Scale (PFS-16) (24, 25, 28), 
Fatigue Severity Scale (FSS) (18, 31), and the Krupp Fatigue 
Severity Scale (KFSS) (22), whereas apathy was measured using 
the Starkstein Apathy Scale (SAS) (25), the Apathy Scale (AS) 
(22), and the Lille Apathy Rating Scale (LARS) (34). For further 
detail, see Table 2.
Methodology Quality
The studies selected were randomized (17–36), one study used 
a crossover design (35), four studies randomized into multiple 
intervention groups (23, 28, 29, 34), while the rest used as a 
control group (17, 18, 20–22, 24–27, 30–33, 36). Three of the 
studies stratified the groups for intervention (31, 32, 34). Sixteen 
of the studies had a blinded component, with 1 (19) being double 
blinded as participants were unaware which group they were 
randomized to (speed or mixed treadmill training) and 15 being 
assessor blind (17, 18, 21, 23, 24, 26–32, 34–36). The lack of an 
inactive PD control in some studies may have contributed to bias, 
along with the studies which were unblinded.
Risk of Bias
Risk of bias was assessed using the Cochrane tool for assessing risk 
of bias, which assesses bias in a number of different aspects that 
include random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome 
assessment, blinding of outcome data, selective reporting, and 
other bias (37). Only four studies had a low risk of bias in all 
sections (19, 32, 34, 35), while majority had at least one criterion 
with unknown bias (17, 18, 20, 23–29, 31, 33). Four studies did 
have high risk of bias in one section, three for selective reporting 
due to presenting only some of the data (21, 30, 36), and one for 
blinding of outcome assessment as assessors were not blinded to 
allocation (22). The criterion which was least reported, and thus 
had the highest number of unknown risk of bias was allocation 
concealment (17, 18, 20–31, 33, 36). For more information, see 
Figure S2A in Supplementary Material.
effect on Primary Outcomes
Significant improvements were found in three studies that 
assessed global NMS using UPDRS part 1, MDS-UDPRS part 1, or 
TABLe 2 | non-motor outcomes of studies.
Reference Outcome Change P-value
Cholewa et al. (20)  – UPDRS I Physio = −0.45 points, control = 0.1 points 0.001
Cugusi et al. (25)  – NMSS NW = −23.2 points, control = 1 point <0.05
 – Fatigue (PFS-16) NW = −11.7 points, control = 0.6 point <0.05
 – Depression (BDI-II) NW = −5.2 points, control = 0.4 point <0.005
 – Apathy (SAS) NW = −6.3 points, control = 1 point <0.0005
Duncan and  
Earhart (21)
 – MDS-UPDRS I Tango = −1.62 points, control = 0.42 NS
Modugno et al. (32)  – UPDRS-1 Theater = −0.8 points, control = 0.3 points <0.05
 – Depression (HDRS) Theater = −12.3 points, control = 0.9 points <0.001
 – Daytime sleepiness (ESS) Theater = −7 points, control = −0.3 points <0.001
Miyai et al. (33)  – UPDRS-1 BWSTT = −0.5 points, control = −0.2 points NS
Nadeau et al. (19)  – MDS-UPDRS I Control = −0.7 points, speed TT = −0.4 points, mixed TT = −0.5 points 0.93
 – Depression (BDI-II) Control = −0.6 points, speed TT = −5.8 points, mixed TT = −1.2 points 0.09
 – Cognition (MMSE) Control = −0.1 points, speed TT = 0.7 points, mixed TT = −0.2 points 0.12
Bridgewater and 
Sharpe (30)
 – Depression (LPDQ) Exercise = non-depressed both pre and post intervention, control =  
non-depressed both pre and post intervention
NS
Burini et al. (35)  – Depression (BDI) Group AT1-GQ2: AT = 1 point, GQ = −1 point NS
Group GQ1-AT2: AT = 3 points, GQ = −4 points
Clarke et al. (26)  – Anxiety (HADS) OT = 1.44 points N/A#
 – Depression (HADS) OT = −1.42 points N/A#
David et al. (29)  – Cognition (digit span forwards and  
backwards)
mFC = 0.7 points, PRET = 0.5 points 0.27
 – Cognition (Stroop test) mFC = 0.3 points, PRET = 0.2 points 0.77
 – Cognition (BTA) mFC = 0.1 points, PRET = 0.3 points 0.83
King et al. (34)  – Apathy (LARS) Home = −0.41 points, individual = −2.24 points, group = −0.25 points 0.377
Nocera et al. (27)  – Cognition (digit span backward  
subtest)
TC = 0.5 points, control = −0.7 points 0.08
 – Cognition (letter verbal fluency) TC = 2.4 points, control = −1.3 points 0.39
 – Cognition (categorical verbal fluency) TC = 1.9 points, control = −0.5 points 0.64
 – Cognition (Stroop test score) TC = 3.8 points, control = 0.8 points 0.75
 – Cognition (Trail Marking A) TC = −11.5 s, control = −0.2 s 0.24
 – Cognition (Trail Marking B) TC = −15.4 s, control = −7.8 s 0.52
Park et al. (23)  – Depression (BDI) ESG = −2.67 points, DSG = −1.6 points 0.04
Pohl et al. (17)  – Cognition (text recall test) RGR = 3.5 points, control = 2.3 points 0.63
 – Cognition (symbol digit  
modification)
RGR = 1.5 points, control = 3.5 points 0.18
 – Cognition (Clox and Cube) RGR = 0 points, control = −0.5 points 0.21
 – Cognition (Naming 30 items) RGR = 0.5 points, control = 1 point 1
 – Cognition (Stroop test time) RGR = −2 s, control = −0.5 s 0.54
 – Cognition (PaSMO) RGR = −6.5 s, control = −22 s 0.13
Rios Romenets  
et al. (22)
 – Cognition (MoCA) Total: tango = 0.4 points, control = −0.6 points 0.080
Visuospatial/executive function: tango = 0.1 points, control = −0.2 points 0.362
Attention: tango = 0.2 points, control = 0 points 0.419
Delayed recall: tango = 0.3 points, control = −0.2 points 0.223
 – Depression (BDI) Tango = −0.2 points, control = −0.4 points 0.770
 – Fatigue (KFSS) Tango = −3.5 points, control = 2.6 points 0.057
 – Apathy (AS) Tango = 2.4 points, control = 2.6 points 0.904
Shulman et al. (28)  – Depression (BDI) HIT = 1.43 points, LIT = −0.68 points, S–R = 0.68 points NS#
 – Fatigue (PFS-16) HIT = 0.52 points, LIT = 1.73 points, S–R = 0.55 points NS#
Sturkenboom  
et al. (18)
 – Fatigue (FSS) OT = 0.1 points, control = 0 points 0.846
 – Mood (BDI) OT = −1 point, control = −1 point 0.318
Teixeira-Machado et al. 
(36)
 – Depression (BDI) Depression scores improved for the Feldenkrais group and decreased  
for the control group
0.05
 – Cognition (MMSE) FG = 2.1 points, control = −1.18 points 0.0007
Winward et al. (31)  – Fatigue (FSS) Gym exercise program = −0.4 points, control = −0.36 points NS
(Continued)
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Reference Outcome Change P-value
Xiao and Zhuang (24)  – Sleep (PDSS-2) Total: BQ = −13.72 points, walking = −2.04 points 0.045
Motor symptoms at night: BQ = −5.59 points, walking = −0.75 points 0.049
PD symptoms at night: BQ = −3.28 points, walking = −0.26 points 0.037
Disturbed sleep: BQ = −3.76 points, walking = −0.35 points 0.045
 – Fatigue (PFS-16) BQ = −0.31 points, control = −1.08 points 0.526
Instrument abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale; BDI, Beck Depression Inventory; MMSE, Mini Mental State Examination; HDRS, Hamilton Depression 
Rating Scale; ESS, Epworth Sleepiness Scale; NMSS, Non-Motor Symptom Scale; PFS-16, Parkinson’s Fatigue Scale-16 Questions; SAS, Starkstein Apathy Scale; PDSS-2, 
Parkinson’s Disease Sleep Scale Version 2; MoCA, Montreal Cognitive Assessment; KFSS, Krupp’s Fatigue Severity Scale; AS, Apathy Scale; LARS, Lille Apathy Rating Scale; 
PaSMO, Parallele serial mental operations; FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; BTA, Brief Test of Attention.
Significant values are in bold.
#Marks intra group P-value; NS, non-significant; N/A, not available.
Negative score indicates improvement: UPDRS-1, BDI, HDRS, ESS, PFS-16, SAS, PDSS-2, KFSS, AS, LARS, PaSMO, FSS HADS, Stroop test time, and trail making.
Positive score indicates improvement: MMSE, NMSS, MoCA, BTA, digit span, Stroop test score, letter verbal fluency, categorical verbal fluency, text recall, symbol digit modification, 
Clox and Cube, and naming 30 items.
TABLe 2 | Continued
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NMSS (20, 25, 32), with all other studies showing non-significant 
improvements (19, 21, 33). Depression also improved in 9 of the 
10 studies (18, 19, 22, 23, 25, 26, 28, 32, 36), with statistically 
significant improvements in 4 studies (23, 25, 32, 36). Daytime 
sleepiness showed a significant improvement for active theater 
(32), and Baduanjin Qigong (24) significantly improved for 
both the overall score of the PDSS-2 and numerous subsections. 
Fatigue and apathy were significantly improved in one study (25).
DiSCUSSiOn
In more recent times, non-pharmacological therapies in PD have 
become increasingly acknowledged as beneficial with various 
modalities offered to patient populations.
intervention Design
The study design varied greatly, in particular, when looking at 
frequency and length of intervention. Various studies showed a 
significant improvement in NMS, including two short duration 
(20, 25) and one medium duration studies (36) involving 2–3 ses-
sions/week lasting 45 min to 1 h and a study with a low frequency 
of 6-h long classes (32). Depression was one of the most widely 
studied outcomes, showing significant improvements in a number 
of different activities (23, 25, 32, 36). Significant improvements 
were also seen in sleep (24, 32), fatigue, apathy (25), and cogni-
tion (36).
Although it is widely regarded that exercise affects brain 
plasticity, different exercise types have been found to selectively 
affect various brain regions. Aerobic training demonstrated its 
importance in the aging brain, showing the most benefit in brain 
regions most affected by aging, including prefrontal, superior 
parietal, and temporal cortices in gray matter, and anterior and 
transverse tracts between the frontal and parietal lobes in white 
matter, which are areas involved in cognition and everyday func-
tioning (38). Another study on resistance training had shown 
to significantly change brain regions involved with response 
inhibition, including the left anterior insula which extends into 
the lateral orbital frontal cortex as well as the anterior part of 
the left middle temporal gyrus (39). Participants who underwent 
training twice weekly significantly improved in the Flanker test 
when compared with participants who had 12 months of twice 
weekly balance and tone training. However, participants who 
only performed resistance training once per week did not show 
significant improvements from the control group. This suggests 
that while different exercise types may beneficially affect differ-
ent brain regions, the improvement was not distinguishable in 
this review as different types of exercise showed positive effects 
in global and specific NMS such as sleep. However, fatigue and 
apathy only showed significant improvement in aerobic exercise, 
possibly due to the brain regions primarily involved.
Risk of Bias
Three of the studies showed a high risk of bias in selective report-
ing of outcome measures, highlighting the trends of importance 
to the authors, in particular, those with positive results (21, 30, 
36). With regard to health-care interventions, it is important that 
all data are fully and clearly reported to help guide clinicians 
in decision-making (40). However, the majority of data were 
present or able to be retrieved from the authors in regard to 
the outcomes of interest of this study, alleviating the potential 
bias as a result of underreporting. One study did not blind the 
assessors for data collection, which may have implications on 
data collected (22). Unblinded assessors may exhibit prejudice 
to expectant results (41).
Measurement Tools
Global measures of NMS were measured by UPDRS part1 (20, 
32, 33), the MDS-UPDRS part 1 (19, 21), and NMSS (25). The 
UDPRS and the revised MDS-UPDRS are validated tools devel-
oped to have a compounded scale for numerous characteristics of 
PD (42–44). Additionally, one study used the NMSS, a validated 
comprehensive assessment of NMS in PD (45, 46).
In the MDS taskforce review of ASs, AS was ranked over 
LARS as its sensitivity was yet to be determined (47). The 
fatigue instruments analyzed by the MDS taskforce were the 
FSS and PFS, where FSS is validated for both screening and 
rating severity, while PFS was validated as screening tool. The 
KFS has also been independently validated for the screening of 
fatigue in chronic disease though not specifically validated in 
PD (48). Sleep instruments were also reviewed (49) with the ESS 
been shown to be both valid and reliable (50) and PDSS-2 also 
validated (51).
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COnCLUSiOn
Physical activity may be a suitable non-pharmacological therapy 
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fatigue, cognition, and sleep were significantly improved by 
some form of physical activity. However, the synergistic effects 
of both pharmacological and non-pharmacological treatments 
in PD are still unclear. For an unbiased appraisal of each activity 
type, further research is needed which prioritizes NMS to help 
determine the most beneficial effects of physical activity in this 
complex condition.
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